Q32 Bio Reports Q3 2026 Net Loss of $8.9 Million
Q32 Bio reported a net loss of $8.9 million, or $0.26 per share, for the third quarter of 2026, versus a $7.4 million loss, or $0.60 per share, a year earlier. Cash and cash equivalents totaled $289.6 million at September 30, 2026.
Q32 Bio reported a third-quarter 2026 net loss of $8.9 million, or $0.26 per share, compared with a net loss of $7.4 million, or $0.60 per share, a year earlier. Cash and cash equivalents totaled $289.6 million at September 30, 2026. The company reported additional clinical findings for bempikibart…